By Denny Jacob

Quince Therapeutics said it intends to advance trials on EryDex following the U.S. Food and Drug Administration's hold being lifted on EryDel's investigational new drug application.

The biotechnology company said it intends to advance a clinical trial to evaluate the safety and efficacy of EryDex for the potential treatment of Ataxia-Telangiectasia, a rare and fatal pediatric neurological disease, pending the close of its acquisition of EryDel. The FDA had imposed a partial clinical hold on the application for EryDex.

"This pivotal trial will be conducted under a Special Protocol Assessment that has already been reviewed with the FDA," said Quince Chief Executive Dirk Thye, "which should allow for the submission of a new drug application following completion of this single study, assuming positive results."

Quince said its acquisition is expected to close in the fourth quarter.

Write to Denny Jacob at denny.jacob@wsj.com

(END) Dow Jones Newswires

September 28, 2023 16:38 ET (20:38 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Quince Therapeutics (NASDAQ:QNCX)
Gráfica de Acción Histórica
De Abr 2024 a May 2024 Haga Click aquí para más Gráficas Quince Therapeutics.
Quince Therapeutics (NASDAQ:QNCX)
Gráfica de Acción Histórica
De May 2023 a May 2024 Haga Click aquí para más Gráficas Quince Therapeutics.